Reduced‐intensity HCTHypomethylating agents (5‐azacitidine or decitabine) every 4‐6 weeks until progressionGemtuzumab ozogamicin 2 mg/m2 on day 1 every 4 weeks up to 8 continuation courses (CD33‐positive)Continue enasidenib (IDH2‐mutated AML) or ivosidenib (IDH1‐mutated AML) until progression. Here, IDH2 is linked to acute myeloid leukemia.